References
- Smith BD , SmithGL, HurriaA, HortobagyiGN, BuchholzTA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol.27(17) , 2758–2765 (2009).
- Huber MA , KrautN, BeugH. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol.17(5) , 548–558 (2005).
- Al-Hajj M , WichaMS, Benito-HernandezA, MorrisonSJ, ClarkeMF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA100(7) , 3983–3988 (2003).
- Sun L , MathewsLA, CabarcasSM et al. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells doi:10.1002/stem.1394 (2013) (Epub ahead of print).
- Matheu A , ColladoM, WiseC et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 72(5) , 1301–1315 (2012).
- Sakai D , SuzukiT, OsumiN, WakamatsuY. Cooperative action of Sox9, Snail2 and PKA signaling in early neural crest development. Development133(7) , 1323–1333 (2006).
References
- Doyon Y , CayrouC, UllahM et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 21(1) , 51–64 (2006).
- Helbing CC , VeilletteC, RiabowolK, JohnstonRN, GarkavtsevI. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res.57(7) , 1255–1258 (1997).
- Soliman MA , BerardiP, PastyryevaS et al. ING1a expression increases during replicative senescence and induces a senescent phenotype. Aging Cell 7(6) , 783–794 (2008).
- Gunduz M , OuchidaM, FukushimaK et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res. 60(12) , 3143–3146 (2000).
- Chen L , MatsubaraN, YoshinoT et al. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res. 61(11) , 4345–4349 (2001).
- Shen DH , ChanKY, KhooUS et al. Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis 26(4) , 855–863 (2005).
- Yu L , ThakurS, Leong-QuongRY et al. Src regulates the activity of the ING1 tumor suppressor. PLoS One 8(4) , e60943 (2013).
- Guerillon C , LarrieuD, PedeuxR. ING1 and ING2: multifaceted tumor suppressor genes. Cell. Mol. Life Sci. doi:10.1007/s00018-013-1270-z (2013) (Epub ahead of print).
References
- Cebrian A , PharoahPD, AhmedS et al. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 27(8) , 1661–1669 (2006).
- Giacinti L , ClaudioPP, LopezM, GiordanoA. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist11(1) , 1–8 (2006).
- Kullmann K , DeryalM, OngMF et al. DNMT1 genetic polymorphisms affect breast cancer risk in the central European Caucasian population. Clin. Epigenetics5(1) , 7 (2013).
References
- Wang ZY , ChenZ. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood111(5) , 2505–2515 (2008).
- de Thé H , ChenZ. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer10(11) , 775–783 (2010).
- Arteaga MF , MikeschJH, QiuJ et al. The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell 23(3) , 376–389 (2013).
- Schenk T , ChenWC, GollnerS et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18(4) , 605–611 (2012).
References
- Chapman PB , HauschildA, RobertC et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26) , 2507–2516 (2011).
- Nigro CL , WangH, McHughA et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J. Invest. Dermatol. 133(5) , 1278–1285 (2013).
- Ruf W , SeftorEA, PetrovanRJ et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 63(17) , 5381–5389 (2003).
- Seftor RE , HessAR, SeftorEA et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am. J. Pathol. 181(4) , 1115–1125 (2012).